Calithera Biosciences (CALA) Competitors $0.0074 +0.00 (+2.78%) (As of 02:15 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSustainabilityTrends CALA vs. TCON, SEEL, HSTO, NAVB, VAXX, SCPS, AMPE, ARDS, STAB, and CMRAShould you be buying Calithera Biosciences stock or one of its competitors? The main competitors of Calithera Biosciences include TRACON Pharmaceuticals (TCON), Seelos Therapeutics (SEEL), Histogen (HSTO), Navidea Biopharmaceuticals (NAVB), Vaxxinity (VAXX), Scopus BioPharma (SCPS), Ampio Pharmaceuticals (AMPE), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), and Comera Life Sciences (CMRA). These companies are all part of the "pharmaceutical products" industry. Calithera Biosciences vs. TRACON Pharmaceuticals Seelos Therapeutics Histogen Navidea Biopharmaceuticals Vaxxinity Scopus BioPharma Ampio Pharmaceuticals Aridis Pharmaceuticals Statera Biopharma Comera Life Sciences Calithera Biosciences (NASDAQ:CALA) and TRACON Pharmaceuticals (NASDAQ:TCON) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Does the media refer more to CALA or TCON? In the previous week, Calithera Biosciences had 1 more articles in the media than TRACON Pharmaceuticals. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for TRACON Pharmaceuticals. Calithera Biosciences' average media sentiment score of 0.00 equaled TRACON Pharmaceuticals'average media sentiment score. Company Overall Sentiment Calithera Biosciences Neutral TRACON Pharmaceuticals Neutral Does the MarketBeat Community prefer CALA or TCON? Calithera Biosciences received 74 more outperform votes than TRACON Pharmaceuticals when rated by MarketBeat users. Likewise, 57.21% of users gave Calithera Biosciences an outperform vote while only 56.57% of users gave TRACON Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCalithera BiosciencesOutperform Votes34157.21% Underperform Votes25542.79% TRACON PharmaceuticalsOutperform Votes26756.57% Underperform Votes20543.43% Which has stronger valuation & earnings, CALA or TCON? TRACON Pharmaceuticals has higher revenue and earnings than Calithera Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalithera Biosciences$9.75M0.00-$39.65MN/AN/ATRACON Pharmaceuticals$12.05M0.01-$3.59M$3.730.01 Which has more volatility & risk, CALA or TCON? Calithera Biosciences has a beta of -1.09, indicating that its share price is 209% less volatile than the S&P 500. Comparatively, TRACON Pharmaceuticals has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Do institutionals and insiders believe in CALA or TCON? 11.6% of TRACON Pharmaceuticals shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by insiders. Comparatively, 5.3% of TRACON Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is CALA or TCON more profitable? Calithera Biosciences' return on equity of 0.00% beat TRACON Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Calithera BiosciencesN/A N/A N/A TRACON Pharmaceuticals N/A -237.65%57.29% Do analysts recommend CALA or TCON? TRACON Pharmaceuticals has a consensus price target of $60.00, indicating a potential upside of 143,440.67%. Given TRACON Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe TRACON Pharmaceuticals is more favorable than Calithera Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calithera Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00TRACON Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryTRACON Pharmaceuticals beats Calithera Biosciences on 8 of the 13 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Calithera Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALA vs. The Competition Export to ExcelMetricCalithera BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36,000.00$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E RatioN/A5.5095.1214.22Price / Sales0.00375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book-0.0210.276.976.37Net Income-$39.65M$153.22M$118.73M$225.56M7 Day PerformanceN/A-1.19%-1.22%-0.02%1 Month PerformanceN/A-6.71%-3.07%2.04%1 Year PerformanceN/A32.39%32.52%28.00% Calithera Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALACalithera BiosciencesN/A$0.01+2.8%N/A-76.0%$36,000.00$9.75M0.0060TCONTRACON Pharmaceuticals1.1979 of 5 stars$0.04+39.3%$60.00+143,440.7%-99.1%$143,000.00$12.05M0.0120Analyst ForecastGap UpSEELSeelos TherapeuticsN/A$0.38+8.6%N/A-99.9%$141,000.00$2.20M0.0020Gap UpHSTOHistogenN/A$0.03flatN/A-92.6%$115,000.00$19,000.00-0.017Gap UpNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-98.3%$100,000.00$70,000.000.0010VAXXVaxxinityN/A$0.00flatN/A-100.0%$25,000.00$70,000.000.0090SCPSScopus BioPharmaN/A$0.00flatN/A-99.3%$13,000.00N/A0.009AMPEAmpio PharmaceuticalsN/A$0.01+∞N/A-99.6%$11,000.00N/A0.0020Gap DownARDSAridis PharmaceuticalsN/AN/AN/AN/A$10,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A+0.0%$10,000.00$1.49M0.0020CMRAComera Life SciencesN/A$0.00flatN/A-99.5%$9,000.00$630,000.000.002 Related Companies and Tools Related Companies TCON Competitors SEEL Competitors HSTO Competitors NAVB Competitors VAXX Competitors SCPS Competitors AMPE Competitors ARDS Competitors STAB Competitors CMRA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CALA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calithera Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CALA Stock Alerts